title: Short-term intravenous fish oil and pediatric intestinal failure associated liver disease: 3-year follow-up on liver function and nutrition.
abstract: Intravenous fish oil (FO) has changed the management of intestinal failure associated liver disease (IFALD). This report describes two IFALD patients who received FO for 5 and 10 months, respectively and reports on their 3-year follow-up.
authors: Department of Pediatrics, Division of Neonatology and Developmental Biology, David Geffen School of Medicine, University of California, Los Angeles, Mattel Children's Hospital, Los Angeles, CA 90095, USA. KCalkins@mednet.ucla.edu
authors: Kara
authors: K
authors: Calkins
authors: Allison
authors: A
authors: Lowe
authors: Stephen B
authors: SB
authors: Shew
authors: James C Y
authors: JC
authors: Dunn
authors: Laurie
authors: L
authors: Reyen
authors: Douglas G
authors: DG
authors: Farmer
authors: Sherin U
authors: SU
authors: Devaskar
authors: Robert
authors: R
authors: Venick
mesh_terms: D005217:Fat Emulsions, Intravenous / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000627:therapeutic use*; D005500:Follow-Up Studies; D048550:Hepatic Insufficiency / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D008111:Liver Function Tests; D010288:Parenteral Nutrition / Q000379:methods*; D012778:Short Bowel Syndrome / Q000150:complications* / Q000628:therapy
chemical_list: D005217:Fat Emulsions, Intravenous; D005395:Fish Oils